Brokerages expect that Aratana Therapeutics Inc (NASDAQ:PETX) will announce $4.72 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Aratana Therapeutics’ earnings. The lowest sales estimate is $4.30 million and the highest is $4.96 million. Aratana Therapeutics posted sales of $5.16 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 8.5%. The business is scheduled to report its next earnings results on Thursday, August 2nd.
On average, analysts expect that Aratana Therapeutics will report full year sales of $26.62 million for the current fiscal year, with estimates ranging from $18.80 million to $38.05 million. For the next financial year, analysts forecast that the firm will report sales of $46.93 million per share, with estimates ranging from $31.80 million to $56.70 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Aratana Therapeutics.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Aratana Therapeutics had a negative net margin of 168.26% and a negative return on equity of 38.97%. The business had revenue of $4.04 million during the quarter, compared to the consensus estimate of $6.06 million.
Several research analysts have commented on the stock. BidaskClub upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, May 10th. HC Wainwright set a $10.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 7th. ValuEngine upgraded shares of Aratana Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 2nd. CL King upgraded shares of Aratana Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research report on Monday, March 12th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $8.68.
NASDAQ PETX traded down $0.02 on Friday, hitting $4.22. The stock had a trading volume of 178,715 shares, compared to its average volume of 372,188. Aratana Therapeutics has a one year low of $3.67 and a one year high of $7.67. The company has a current ratio of 3.37, a quick ratio of 2.82 and a debt-to-equity ratio of 0.15. The stock has a market cap of $198.62 million, a price-to-earnings ratio of -4.35 and a beta of 2.88.
In other news, insider Peter Steven St sold 11,513 shares of the stock in a transaction that occurred on Monday, April 30th. The shares were sold at an average price of $5.00, for a total value of $57,565.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Brent Standridge sold 10,000 shares of the stock in a transaction that occurred on Monday, June 25th. The shares were sold at an average price of $4.56, for a total transaction of $45,600.00. Following the completion of the transaction, the chief operating officer now owns 99,967 shares of the company’s stock, valued at $455,849.52. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. MetLife Investment Advisors LLC bought a new position in shares of Aratana Therapeutics in the fourth quarter valued at approximately $110,000. Ellington Management Group LLC bought a new position in shares of Aratana Therapeutics in the fourth quarter valued at approximately $304,000. Goldman Sachs Group Inc. boosted its holdings in shares of Aratana Therapeutics by 35.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 17,677 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Aratana Therapeutics by 683.0% in the first quarter. Jane Street Group LLC now owns 81,952 shares of the biopharmaceutical company’s stock valued at $361,000 after acquiring an additional 71,486 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in shares of Aratana Therapeutics by 23.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 17,300 shares in the last quarter. Institutional investors and hedge funds own 67.04% of the company’s stock.
About Aratana Therapeutics
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.